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Results; Pl,s randomized to oath or ETT did not differ significantly in age, 
o~ TT gender or clinical risk l,scl,ors, Cath shewed no CAD tn 102/124 (82 ,~). E 
wee nag In 116/1~5 (93%), FIU was available In 84% of 216 pts eligible 
for 9 month F/U, Nag ceth pts had no difference in recurrence of CP but 
significantly lass ER and outpatient visits compared to nag ETT pts (Table), 
Gon¢lus/ons: Immediate nag ceth compared to nag ETT may result, in 
dooreased Iong,l,erm resource utilization, Immediate oath could be an alter. 
native to ETT In low-risk CP pl,s, 
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~ Simon for Risk StrntlfloMIon In E©hoosrdlogrsphy 
Woman With Chest Pain 
L, Colllglanl, C, Dodl, E, Peollni, G, Shine, E, NannlnL C~lrdiova~cHlar 
Un~t~. Ho~Dltal, Of Lucca end Octal,alia. ffal,y 
Bac~gro¢~ncl: St,mac ~hooerdlogrephy Is widely accepted ae ~ dtpgno,'~l,lg 
tool, but the pmgnosl,lc v~lue of phermacologlenl stress ocho~ardiography 
(SE) In women with chest pain mm~lns lit.defined, 
Mel,hOal~: 443 women (63 ~ 10 yoar~', mean :L S~D) with no pmvloue 
evtdanc~ O! comnsty arroW/disease (CAD) undenNenl, ~E with either dobu. 
tamlne (n ~ 1.'t9, up to 40 vgr/k0/mln + atropine up to I rag) or dlpynd~melo 
(n = ~04, (.~D tn 0,84 mg ovor 10' ÷ ~troplna up to t rag) far ev,~lual,ien el 
chest pain, The dev01opmont el, new regional f~lnctlon~l ebnon.aiitios wa~ 
¢on~,ldered ae the only criteria tar test poall,ivlty, 
Re~l~l,t~: ,~E wa~, positive in 51 pal,feats and i~eg~tiva in 392, D~.lring P, 
follow,tlp el, 35 t 16 months, 2;~ sponl,aneeua evenl,s o(~curmd'. 3 eardiae 
doe~ha (CDL 10 myeemdial inl,metione (MI), and 0 unst~blo ~mgina (UA), 
Momov0r, P.0 patleot~, tlndenNent coronary r~vnscul~rl~ation, of whom 16 
with pOSitive and 4 wll,h negative SE (p • 0,0001), Among 10 cltnt¢,~t and 
SE considered variablos, the posit,lye result el, SE (R'R = 70,0', 95% CI ,= 
8,0-624,3; p ~ 0,0001) was the only Independently associated with hard 
ovenl,a (CD + MI) at Cox analysls, When all the spontaneous events were 
considered (CD + MI + UA) the positive result ot SE (R'R = 34,1; 95% CI = 
f0,9-f06,7; p < 0,0001) and l,amlliar hlston/of CAD (R'R = 3,1; 95% CI = 
1 ,~,7,0', p < 0,02) were f~,~ld to be multivariate predictors el, outcome 
Conclusions: SE showed offecttvonoss for ask stratil,ication of women with 
chest pain also wl~en csrdtae hard events were conmdomd as prognostic 
endpolnts. 
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~ Unstable Angina Guideline Is Assoclaled With 
Improved Outcomes 
R,P, Glugltane, C,A, Camsrgo, Jr,, M.A. Makary, D,M, Lloyd-Jones, 
C,J. O'Donnell, Harvard Medical School an# Han,arcl School of Public 
H~lth, Elos~on, MA 021 iS, USA 
EL, tck£/round: An unstable nngina (UA) guideline was publlsl~ed in 1994 by 
the Agency l,or Health Care Policy and Research (AHCPR); however, tt is 
unknown if following the guideline Improves patient outcomes, 
&#el'hods: We retrospectively reviewed 260 consecutive non-referral ad- 
missions to an intensive cam or telometn/unit with prtman/UA tn t 992. Care 
was considered concordant with the geldotlne It 280% el 8 important roc- 
ommendatlees wore followed, Stratified Kaplen-Melor and multlvanato Cox 
Models were used to assess the association of guideline care with 1 year 
suwlval in the 275 patients alive at discharge. 
Re.~utts; There wore 25 deaths and 21 MIs by 1 yr post discharge. 
Guldoliee care was assoclnted w~th improved 1 yr sun/ival in the crude 
analysis (below) and in a model adjusted l,or ago, sex, and comorbldity 
(OR = 0,37 [95% CL 0,16 to 0.83]). High-risk subgroups (elderly, CHF on 
presentation) benefitted most. Results were similar for 1 yr survival free of 
Mr. 
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Conclusions: Care as  outlined in the AHCPR UA gt, ideline may improve 
outcomes when applied to those most likely to benefit. Prospective eval- 
uation of this guideline in a larger cohort would allow futher evaluation of 
confounders. 
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~ Roxlthromy©ln In the Non.Q-Wave Events= Coronary 
Final Rnulta o! the ROXIS Study at 6 Months 
Follow-up 
E, Gudinkol, G, Bozovich, I, MOIalI, E, Beck, D, Mautner, For tt~ ROXtS 
Stucty Group; Favatoro Foundation and Owens Ho~,plfat. B¢~no~ Attar, 
Argentina 
Background: Them am cumulative evidences o! tim mlatlonship t~t '~n 
Ct~l,amydi~ pneumonlae and coronary mleP/die.ca,  We ,:xmdu~ed the 
recent ROXB Study in order to te~t he eflioao/el an oral m~folide anfibiop¢, 
toxlthmmy~tn, In patients euffeflng ~cut~ non,Q-wave coron~/events, 
Method, Double,blind, mn~mi~od, multteentm, pla~;'ebo,coNfolled sitka'. 
We prospect,Ivory inolud~d 20;~ i~tienfa whlthin ~4 h Of the onset el unstal~le 
angina or non,Q wavo myo~ardlel infamtlon who reomv~l ~ .yen_ tional anti~. 
rhemto end ant!(~ag~llant therapy plus either oral relithmmycth 150 mg.,IB!D 
or plac~sbe for 30 days, Prlm~n/effic'a W endpomls were severe ~¢unent 
ischemie, acul,e myocardial infamtion and death, Effiea W asses~t  was 
schnduled at 30, g0 and tad day~ following admission, 
Event Pl~l~eha te = tOOt R0~ith~'omvcm in =!02) 
Regiment anQm~ 5 
ACUte tnMfctt~n ~ a 
Death 2 a 
T1"Ipla ondpolnt' .q 2 
i p '~ O032 
Six,month follow.up will be completed and results ttvaitable fm presents. 
l,ion at the beginning Of 1998, 
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~ Oeprosslon Influences 1*Year Prognosis in Unstable 
Angina 
F, Lesp0rance, N. Frasum.Smith, P Thoroux. &fontreal, Heart tnsMute arK/ 
McGiII Universi~; Montreal. Quebec, Canada 
Background: We previously demonstrated the prognostic importance o! de- 
prassion l,ollowmg MI. This study was pedonned to see i1 the results would 
be the same for patients with unstable angina. 
Met,hods: Between 1994 and 1996 the Beck Depression Inventon/(BD|) 
was administered to 510 patients dunng admission for unstable angina 046 
women). There was no age limit (moan = 61.9 ± 10.4 yearn). All patients 
received usual physician care Patients were recontactnd at t2 months to 
assess outcomes. Logistic regression was used to evaluate the impact o~ 
depression on the combined end-point o1 MI or death both bolero and alley 
control tot other predictors Of prognosis. 
Result. Overall 41% (208) of patients had SOl scores : 10 Imtld/moderate 
depression), By 1 year 14 pts died oi cardiac causes, and 14 suffered a 
non-fatal MI The odds ratio (OR) for cardiac death or M! associated with an 
elevated BDI, score was 3.3 (95% CI = 1 3, 7.4; p = 0.0043). Depmsston's 
impact on prognosis remained alter control for the other signdicant predictors 
in the data set: age, previous unstable angina, previous revascuMrization, 
and revaScularization during the cunent admission (adjusted OR = 3.0; 95% 
CI = 1,3, 6,9: p = 0 .0076) ,  
Conclusions: These results extend the evidence of a prognostic impact 
el, depression to patients with unstable angina. Depression constitutes a ask 
for all acute coronary syndrome patients. 
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~Late  Diverging Event Curves for Survival Following 
lib/Ilia Antagonism in Patients With Unstable 
Angina: PARAGON Study 1-Year Follow-up 
D.J. Moliterno, R.A. Harrington, K.L Newby, PW. Armstrong, F. Van de 
Wed, HD. White, R.M. Califf, E.J. Topoi. For the PARAGON Study 
Investigators; Cleveland Clinic Foundation, Cleveland, OH, USA 
Despite current therapies, unstable angina and non-Q-wave MI are still as- 
sociated with substantial morbidity and mortality; large-scale studies have 
shown the 30-day mc~rtality to be approximately 3%, and this increases 
2- to 3-fo~d i .  the first year. We report the first Iongterm follow-up el the 
use a platelet Ilblllla inhibitor, lamifiban, in such patients. In PARAGON, 
2,282-patients were randomized in a double-blinded fashion to 72 hours of 
IV hepann (control group), high-dose lamifiban ~ heparin, or low-dose lami- 
fiban J: hepadn. All patients received aspirin, and the baseline characteristics 
of the groups were similar. At 30-day follow.up, no mortality difference was 
noted among the groups (2.9%, 3.6%, and 3.0%, respectively). In contrast. 
mortality was ~educed by 21% in comparison to control by low-dose lamifiban 
